07:45 AM EST, 11/22/2024 (MT Newswires) -- Merck ( MRK ) said Friday it has received approval for Welireg from China's National Medical Products Administration to treat adults with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas or pancreatic neuroendocrine tumors.

The approval was based on the results of a phase 2 study, Merck ( MRK ) said.

Welireg, or belzutifan, is approved in the US for the same indication as well as for previously treated advanced renal cell carcinoma, the company said.